Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diabegone
- Development stage
- Preclinical
- Lead developer
- Shanghai Innogen Pharmaceutical Technology
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Diabegone is a recombinant GLP-1 fusion protein biologic being developed by KPC (Kunming Pharmaceutical Group) for the treatment of diabetes. As a Glucagon-like peptide 1 receptor (GLP-1R) agonist, it mimics the physiological effects of the endogenous GLP-1 hormone, which include the stimulation of glucose-dependent insulin secretion and the suppression of glucagon release. The fusion protein modality is typically designed to extend the circulating half-life of the GLP-1 peptide, potentially allowing for a more convenient dosing schedule compared to native GLP-1. It is currently listed in the company's innovation pipeline for metabolic diseases.
- Brand names
- Diabegone
- Other names
- GLP-1 fusion proteinGLP1 fusion proteinGLP 1 fusion proteinRecombinant human GLP-1-Fc fusion protein
02
Targets
Beyond the preview
Go deeper on Diabegone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Diabegone.